Containment Generic Pharmaceutical Marketing 
The Pharma Data
MAY 8, 2021
The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.
The Pharma Data
JUNE 17, 2022
With a strong portfolio of eight marketed biosimilars and a further 15+ in various stages of development, Sandoz has an unparalleled heritage and extensive expertise in the development, manufacturing and delivery of biosimilar medicines to patients and the healthcare community worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 23, 2020
This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. The Company is marketing these products globally, in over 150 countries.
The Pharma Data
DECEMBER 23, 2020
COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.
The Pharma Data
APRIL 4, 2023
With eight marketed biosimilars Sandoz is offering the broadest biosimilar portfolio and is the leading biosimilars company in Europe with more than two decades of experience. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.
The Pharma Data
MAY 2, 2021
With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems. The Sandoz division has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. Disclaimer.
The Pharma Data
MAY 18, 2021
By modernizing and simplifying its manufacturing setup, Sandoz will improve its ability to consistently deliver high-quality medicines to patients, while remaining cost-competitive on the global market. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. About Sandoz.
Expert insights. Personalized for you.
52 
Let's personalize your content